Institutional ownership · Form 13F
CCCC institutional ownership
C4 Therapeutics, Inc. - Common Stock: reported institutional holdings as of 2026-06-30 (filed through 2026-08-31), aggregated by StockEyes from SEC Form 13F information tables. CCCC is one of 2732 tickers in the validated publication set. Mapping coverage in this publication set: 4562 of 6046 universe tickers have at least one validated CUSIP mapping (75.5%). Latest-quarter filed value resolved to any listed ticker: 77.3%; resolved to this universe: 77.2%.
CCCC: change since the prior quarter's filings
More managers reported a position, with the count rising from 123 in the quarter ended 2026-03-31 to 148 in the quarter ended 2026-06-30 (+25, 20.3%). Total reported shares rose to 117,624,878 (+32,680,405, 38.5%), moving the same way as the manager count. Among the 22 managers listed as top holders in both quarters, the largest increases were BlackRock, Inc. (+5,848,192 shares) and Squadron Capital Management LLC (+4,950,000 shares), among 17 managers who added shares, and the largest decreases were RENAISSANCE TECHNOLOGIES LLC (-1,271,987 shares) and Soleus Capital Management, L.P. (-425,961 shares), among 3 managers who reduced shares. Ikarian Capital, LLC (2,433,000 shares), STATE STREET CORP (2,115,621 shares) and 6 more entered the listed top holders; MILLENNIUM MANAGEMENT LLC (1,393,342 shares in the prior quarter), JANE STREET GROUP, LLC (1,246,896 shares in the prior quarter) and 6 more dropped out of the listed top holders.
New to 13F data? Read how to read a 13F filing, or see where institutions moved overall in the Smart Money Report.
Reported totals, quarter ended 2026-06-30
148 reporting managers held 117,624,878 shares, reported value $537,796,475 exactly as filed. Values are position values transcribed from the filings, not current market prices.
Reported quarter-over-quarter change (quarter ended 2026-03-31 to quarter ended 2026-06-30): reporting managers +25, reported shares +32,680,405 (+38.47%), reported value +147.93%. These changes compare two filing snapshots.
Shares outstanding check: 123,025,136 shares reported by the issuer (SEC XBRL, period ended 2026-07-31). Reported 13F shares equal 95.6% of that figure. This page passed the publication sanity gate before listing.
CCCC in this quarter's filings
Concentration check: the largest reported position, MORGAN STANLEY with 8,867,338 shares, is 7.5% of all shares reported for CCCC this quarter. The five largest reporting managers together account for 33.4% of the reported total, so the headline total is spread across a broad manager base rather than a few holders.
Reported quarter-over-quarter change: the reporting-manager count rose by 25 versus the quarter ended 2026-03-31, and reported shares moved +38.47% (+32,680,405 shares). That is a comparison of two filing snapshots, not a record of trades on any single day.
Shares-outstanding cross-check: reported 13F shares equal 95.6% of the issuer share count used at the publication gate (123,025,136 shares, issuer period ended 2026-07-31). The gate publishes a ticker only when that relationship is plausible; lending chains can push reported totals above a simple ownership share, which is why the figure is a sanity check and not an ownership percentage.
Largest reporting managers, CCCC
| # | Manager | Shares | Value as filed | Share of reported total |
|---|---|---|---|---|
| 1 | MORGAN STANLEY | 8,867,338 | $41,410,468 | 7.5% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8,000,000 | $37,360,000 | 6.8% |
| 3 | BlackRock, Inc. | 7,896,718 | $36,877,672 | 6.7% |
| 4 | Lynx1 Capital Management LP | 7,326,691 | $34,215,647 | 6.2% |
| 5 | Squadron Capital Management LLC | 7,200,000 | $33,624,000 | 6.1% |
| 6 | Bain Capital Life Sciences Investors, LLC | 7,171,910 | $33,492,820 | 6.1% |
| 7 | JPMORGAN CHASE & CO | 4,747,424 | $20,651,295 | 4.0% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4,417,731 | $20,630,804 | 3.8% |
| 9 | CITADEL ADVISORS LLC | 4,187,580 | $19,555,999 | 3.6% |
| 10 | GOLDMAN SACHS GROUP INC | 3,530,991 | $16,489,728 | 3.0% |
| 11 | WASATCH ADVISORS LP | 3,522,644 | $16,450,747 | 3.0% |
| 12 | TWO SIGMA INVESTMENTS, LP | 3,469,707 | $16,203,532 | 2.9% |
| 13 | Soleus Capital Management, L.P. | 3,377,981 | $15,775,171 | 2.9% |
| 14 | SILVERARC CAPITAL MANAGEMENT, LLC | 3,032,060 | $14,159,720 | 2.6% |
| 15 | BANK OF AMERICA CORP /DE/ | 2,656,359 | $12,405,197 | 2.3% |
Manager names and figures are transcribed from each manager's own Form 13F information table. A manager listing shares in this snapshot does not mean it holds them today.
Reported change, 2026-03-31 to 2026-06-30
| Quarter ended | Filed through | Reporting managers | Reported shares | Value as filed |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-29 | 123 | 84,944,473 | $216,912,908 |
| 2026-06-30 | 2026-08-31 | 148 | 117,624,878 | $537,796,475 |
Every change figure on this page is a reported quarter-over-quarter change between filing snapshots. It is not real-time trading activity.
CCCC reported totals over time
Quarter ended 2026-06-30: 148 reporting managers · 117,624,878 reported shares · $537,796,475 value as filed.
The full archived series is part of StockEyes Pro. Continue with Google to sign in.
Quarter-end 13F filed data, long positions only; filings arrive up to 45 days after quarter end.
CUSIPs behind the CCCC total
The validated bridge mapped 1 current CUSIP(s) to CCCC for this quarter: 12529R107. Option pseudo-CUSIPs, units, warrants, and preferred classes are excluded from these common-share totals. Mapping coverage in this publication set: 4562 of 6046 universe tickers have at least one validated CUSIP mapping (75.5%). Latest-quarter filed value resolved to any listed ticker: 77.3%; resolved to this universe: 77.2%.
What this page is and is not
Form 13F reports are quarterly holdings snapshots. Managers file up to about 45 days after quarter-end, so these figures describe reported positions as of the quarter-end date, not holdings today. 13F lists reportable long positions from managers above the SEC reporting threshold and omits short positions entirely.
This page is informational only. It is not investment advice, a recommendation, or a signal to buy or sell. Source: SEC Form 13F bulk data set for filings through 2026-08-31 (period ended 2026-06-30), joined to tickers through StockEyes' validated CUSIP bridge. Methodology and coverage are documented on the institutional ownership hub.
Insider transactions for CCCC (officer and director buys and sells) are covered by InsiderTrace: insidertrace.com/stock/cccc. StockEyes does not duplicate insider transaction tables.
Related StockEyes pages
Latest headlines tagged CCCC are on the market news wire. Upcoming earnings and market dates are on the events calendar. The term itself is defined in the institutional investor glossary entry, and the research workflow behind pages like this one is walked through in how to research a stock and how to compare SEC filings.